Investors

Development Pipeline

This is the development pipeline as of July 22, 2024

Development Pipeline (As of the latest Announcement of business results)(502 KB)

1. Oncology

As of July 22, 2024

Product Name/
Development Code/
Generic Name		 Mechanism Dosage Form Target Indication Phase* Area Licensor
Ⅰ Ⅱ Ⅲ F
Opdivo
Intravenous
Infusion		 Anti-PD-1 antibody Injection Hepatocellular carcinoma
 
 
 
 
 
 JP・KR In-house
(Co-developed with BMS)
Bladder cancer
 
 
 
 
 
 JP・KR・TW
Yervoy
Injection★		 Anti-CTLA-4 antibody Injection Gastric cancer
 
 
 
 
 
 JP・KR・TW Co-developed with BMS
Urothelial cancer
 
 
 
 
 
 JP・KR・TW
Hepatocellular carcinoma
 
 
 
 
 
 JP・KR
ONO-7913/
Magrolimab		 Anti-CD47 antibody Injection Pancreatic cancer★
 
 
 
 
 
 JP Gilead
Colorectal cancer★
 
 
 
 
 
 JP
ONO-4482★/
Relatlimab		 Anti-LAG-3 antibody Injection Melanoma
 
 
 
 
 
 JP Co-developed with BMS
Hepatocellular carcinoma
 
 
 
 
 
 JP・KR・TW
ONO-7475/
Tamnorzatinib		 Axl/Mer inhibitor Tablet Pancreatic cancer★
 
 
 
 
 
 JP In-house
EGFR-mutated non-small cell lung cancer
 
 
 
 
 
 JP
ONO-4578 PG receptor (EP4) antagonist Tablet Gastric cancer★
 
 
 
 
 
 JP・KR・TW In-house
Colorectal cancer★
 
 
 
 
 
 JP
Pancreatic cancer★
 
 
 
 
 
 JP
Non-small cell lung cancer★
 
 
 
 
 
 JP
Hormone receptor-positive, HER2-negative breast cancer
 
 
 
 
 
 JP
ONO-7427★ Anti-CCR8 antibody Injection Solid tumor
 
 
 
 
 
 JP・US・EU Co-developed with BMS
ONO-7914★ STING agonist Injection Solid tumor
 
 
 
 
 
 JP In-house
ONO-4059 Bruton‘s tyrosine kinase (BTK) inhibitor Tablet Primary central nervous system lymphoma
 
 
 
 
 
 US In-house
ONO-4685 PD-1×CD3 bispecific antibody Injection T-cell lymphoma
 
 
 
 
 
 JP・US In-house
ONO-7018 MALT1 inhibitor Tablet Non-Hodgkin lymphoma, Chronic lymphocytic leukemia
 
 
 
 
 
 US Chordia
ONO-4538HSC Anti-PD-1 antibody Injection Solid tumor
 
 
 
 
 
 JP Co-developed with BMS
ONO-8250 iPSC-derived HER2 CAR T-cell therapy Injection HER2-expressing Solid tumor
 
 
 
 
 
 US Fate

★Combination with Opdivo.

※In the case of clinical development of the oncology drugs in the same indication, the most advanced clinical phase is described.

  • Ⅰ:Phase 1、Ⅱ:Phase 2、Ⅲ:Phase 3:、F:Filed

2. Areas other than Oncology

As of july 22, 2024

Product Name/
Development Code/
Generic Name		 Mechanism Dosage Form Target Indication Phase* Area Licensor
Ⅰ Ⅱ Ⅲ F
Velexbru Tablets/
Tirabrutinib
Hydrochloride		 Bruton‘s tyrosine kinase (BTK) inhibitor Tablet Pemphigus
 
 
 
 
 
 JP In-house
ONO-2017/
cenobamate		 Inhibition of voltage-gated sodium currents/positive allosteric modulator of GABAA ion channel Tablet Primary generalized tonic-clonic seizures
 
 
 
 
 
 JP SKBP
Partial-onset seizures
 
 
 
 
 
 JP
ONO-2910 Enhancement of Schwann cell differentiation Tablet Chemotherapy-Induced Peripheral Neuropathy
 
 
 
 
 
 JP In-house
Diabetic polyneuropathy
 
 
 
 
 
 JP
 
 
 
 
 
 US
ONO-2808 S1P5 receptor agonist Tablet Multiple System Atrophy
 
 
 
 
 
 JP・US In-house
ONO-4685 PD-1×CD3 bispecific antibody Injection Autoimmune disease
 
 
 
 
 
 JP・EU In-house
ONO-2020 Epigenetic Regulation Tablet Neurodegenerative disease
 
 
 
 
 
 US In-house
ONO-1110 Endocannabinoid regulation Oral Pain
 
 
 
 
 
 JP In-house
  • Ⅰ:Phase 1、Ⅱ:Phase 2、Ⅲ:Phase 3:、F:Filed

 

3. Deciphera(Subsidiary)

Learn more about Deciphera pipeline　→

As of July 22, 2024

Product Name/
Development Code/
Generic Name		 Mechanism Dosage Form Target Indication Phase* Area Licensor
Ⅰ Ⅱ Ⅲ F
Qinlock／ripretinib KIT inhibitor Tablet GIST
2nd KIT Exon 11+17/18
 
 
 
 
 
 NA・SA・EU・AU・KR・TW Deciphera
DCC-3014／vimseltinib CSF-1R inhibitor Tablet TGCT
 
 
 
 
 
 NA・EU・AU・HK Deciphera
DCC-3116 ULK inhibitor Tablet Solid tumor（with sotorasib）
 
 
 
 
 
 US Deciphera
Solid tumor（with ripretinib）
 
 
 
 
 
 US
DCC-3084 Pan-RAF inhibitor Tablet Solid tumor
 
 
 
 
 
 US Deciphera
  • Ⅰ:Phase 1、Ⅱ:Phase 2、Ⅲ:Phase 3:、F:Filed
  • NA : North America, SA : South America, AU : Australia, SG : Singapore, HK : Hong Kong, KR : Korea, TW : Taiwan, JP : Japan